EANS-News: AGENNIX AG /dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG
Planegg/Munich (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information
Planegg/Munich (Germany), November 4,
2010 - Agennix AG (Frankfurt Stock Exchange (Prime Standard):
AGX/ISIN DE000A1A6XX4) was informed yesterday that the German Federal
Financial Supervisory Authority (Bundesanstalt fuer
Finanzdienstleistungsaufsicht) (BaFin) has yesterday granted the
Company´s largest shareholder, dievini Hopp BioTech holding GmbH &
Co. KG ("dievini"), and certain other persons and legal entities to
whom dievini´s share ownership is attributed, an exemption from the
obligations pursuant to Section 35 of the German Takeover Act to
publish the acquisition of control, to provide BaFin an offer
document, and to publish a mandatory tender offer to the other
shareholders of Agennix AG in connection with the capital increase of
the Company completed in October 2010.As a result of their participation in the capital increase completed on October 4, 2010, dievini and certain other persons and legal entities to whom dievini´s share ownership is attributed, acquired control of the Company in the meaning of Section 29 (2) of the German Takeover Act and would have been required to make a mandatory tender offer to the other shareholders of Agennix had the exemption not been granted.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company´s most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
end of announcement euro adhoc
Further inquiry note:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade